Peter Angus

Summary

Affiliation: Austin and Repatriation Medical Centre
Country: Australia

Publications

  1. ncbi Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
    Peter Angus
    Austin Hospital, Studley Road, Heidelberg, Victoria 3084, Australia
    Gastroenterology 125:292-7. 2003
  2. ncbi Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital
    Mary Y Y Qian
    Department of Liver Transplantation, Austin Hospital, Heidelberg, Victoria, Australia
    J Gastroenterol Hepatol 25:951-6. 2010
  3. ncbi Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!
    Peter Angus
    Antivir Ther 9:145-8. 2004
  4. ncbi Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance
    Scott Preiss
    Victorian Infectious Diseases Reference Laboratories, Research and Molecular Development, North Melbourne, Victoria, Australia
    Hepatology 48:741-9. 2008
  5. ncbi Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis
    Stuart Roberts
    Department of Gastroenterology, Alfred Hospital, Melbourne, Victoria, Australia
    Clin Gastroenterol Hepatol 5:932-7. 2007

Collaborators

Detail Information

Publications5

  1. ncbi Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
    Peter Angus
    Austin Hospital, Studley Road, Heidelberg, Victoria 3084, Australia
    Gastroenterology 125:292-7. 2003
    ..The aim of this study was to characterize adefovir resistance in a patient who developed clinical and virologic evidence of breakthrough during a 96-week course of treatment...
  2. ncbi Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital
    Mary Y Y Qian
    Department of Liver Transplantation, Austin Hospital, Heidelberg, Victoria, Australia
    J Gastroenterol Hepatol 25:951-6. 2010
    ..Screening patients at high risk of HCC has become standard practice. The aim of this study was to assess the efficacy and cost of screening high-risk individuals for HCC in an Australian tertiary hospital...
  3. ncbi Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!
    Peter Angus
    Antivir Ther 9:145-8. 2004
  4. ncbi Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance
    Scott Preiss
    Victorian Infectious Diseases Reference Laboratories, Research and Molecular Development, North Melbourne, Victoria, Australia
    Hepatology 48:741-9. 2008
    ....
  5. ncbi Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis
    Stuart Roberts
    Department of Gastroenterology, Alfred Hospital, Melbourne, Victoria, Australia
    Clin Gastroenterol Hepatol 5:932-7. 2007
    ..The aims of this study were to investigate the effect of treatment with peginterferon alfa-2a and ribavirin on hepatic venous pressure gradient (HVPG) in CHC with compensated cirrhosis...